In Germany, the forecast for sales of systemic hormonal preparations (excluding sex hormones and insulins) suggests stability, with a value of 2.3% in 2024 and 2.2% from 2025 to 2028 of total sales. Comparing to the 2023 base, these figures indicate a slight decline and then a plateau in market share. The year-on-year analysis shows a minor contraction followed by steady performance. Over a longer term, the Compound Annual Growth Rate (CAGR) suggests negligible annual variation.
Future trends to watch include potential impacts of healthcare policy changes, advancements in hormone therapy innovations, and shifts in demographic healthcare needs which could influence demand patterns.
